A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring

NCT00646880 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: propiverine
DRUG: tolterodine PR

Sponsor

Pfizer